Toxicological Evaluation of Faforon Herbal: A Popular Stem Cell Product Marketed in Nigeria

Abstract

Faforon herbal is a commercially marketed liquid preparation sold in Nigeria under the label of a "stem cell" product and promoted for the prevention or treatment of a wide range of conditions, including infections, fertility problems, and chronic diseases. These broad therapeutic claims have not been independently validated in peer-reviewed research, and regulatory bodies have separately raised general concerns about the marketing of unapproved stem cell-labeled products. Independent of these efficacy claims, this study evaluated the general toxicological safety profile of Faforon herbal using acute and repeated-dose oral toxicity testing in Wistar rats, following Organisation for Economic Co-operation and Development (OECD) test guidelines. In the acute toxicity phase, no mortality or overt signs of toxicity were observed at the limit dose of 5,000 mg/kg body weight, indicating an oral median lethal dose (LD50) greater than 5,000 mg/kg. In the 28-day repeated-dose phase, groups of six rats received distilled water (control) or Faforon herbal at 200, 1,000, or 2,000 mg/kg body weight daily. Body weight, relative organ weights, hematological indices, serum biochemistry, and liver and kidney histology did not differ significantly from control at the low and mid doses. At the highest dose (2,000 mg/kg), relative liver weight, alanine aminotransferase, and aspartate aminotransferase were significantly elevated relative to control (p < .05), and histology showed mild periportal hepatocyte vacuolation, while renal parameters and histology remained unaffected at all doses. These findings indicate a wide margin of safety for Faforon herbal at doses at and above typical recommended consumption levels, with mild, dose-dependent hepatic stress evident only at a substantially supratherapeutic dose. This toxicological safety assessment does not evaluate, and should not be interpreted as validating, the product's marketed regenerative or disease-specific therapeutic claims, which remain scientifically unsubstantiated and require separate, rigorous efficacy research.